Adagio Therapeutics Jump 58% As Monoclonal Antibody Meet Primary Endpoints
(Adagio) Shares of Adagio Therapeutics rose more than 58% on Wednesday after announcing that its monoclonal antibody’s primary endpoints were statistically significant. The company said that in its Phase 2/3…